暴露和粉样前体蛋白加工:对阿尔茨海默病的关注点
Ravikant Sharma1, M D Abubakar2, Priya Bisht2
1Research Institute of Biomedicine, University of Oulu, Aapistie 5, 90014 Oulu, Finland.
Current molecular pharmacology
|November 3, 2023
概括
暴露于,特别是从婴儿期开始,会影响调节认知的大脑区域,并增加粉样蛋白前体蛋白 (APP) 水平. 这篇评论将与阿尔茨海默氏症联系起来.
科学领域:
- 环境毒理学环境毒理学
- 神经科学是一个神经科学.
- 生物化学 生化学
背景情况:
- 在全球范围内,地下水,土壤和食品中的污染超过了安全限值.
- 人类对的暴露增加会导致各种健康问题,包括认知障碍.
- 流行病学研究表明,暴露会对儿童的认知产生负面影响.
研究的目的:
- 审查暴露对粉样蛋白前体蛋白 (APP) 的影响.
- 为了研究和阿尔茨海默氏病的病原体之间的联系.
主要方法:
- 从PubMed和Scopus发表的文章的系统审查.
- 从其前体中分析在粉样β生成中的作用.
主要成果:
- 长期暴露于会改变与认知功能相关的大脑区域.
- 会通过增加RAGE表达来影响血脑屏障 (BBB).
- 通过调节APP及其处理酶 (β-分泌酶, presenilin) 来促进粉样蛋白生成途径.
- 会影响线粒体动力学,DNA修复和表观遗传修饰.
结论:
- 高度暴露会影响粉样蛋白前体蛋白,这是早期阿尔茨海默病发展的关键因素.
- 暴露与阿尔茨海默氏病的发病有关.
相关概念视频
Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197


